Growth Factor Receptor Assay Kits: Accelerate Your Research
Accelerate decisions at the bench and for your business with our family of Growth Factor Assay Kits. No cell culture required.
Showing 1–10 of 15 results
-
FGFR/β-Klotho Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Cardiovascular, NASH/NAFLD, Obesity, Reproduction, Wound Healing
-
FGFR1/2 Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Autoimmune, Cancer, Kidney Disease, NASH/NAFLD, Neurodegenerative, Reproduction, Wound Healing
-
Human EGFR1 Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Cancer, Dermatitis, Kidney Disease, NASH/NAFLD, Neurodegenerative, Obesity, Reproduction, Wound Healing
-
Human G-CSFR Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Autoimmune
-
Human GHR Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Autoimmune, Cancer, Cardiovascular, Dyslipidemia, Kidney Disease, NASH/NAFLD, Obesity, Osteoporosis, Reproduction
-
Human GM-CSFR Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Autoimmune, Cancer
-
Human IGF-1R Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Cancer, Obesity, Reproduction
-
Human INSRb Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Obesity, Reproduction
-
Human M-CSFR Reporter Assay Kit
Species
Human
Target Type
Cytokine Receptor
Growth Factor Receptor
Associated Disease
Autoimmune, Cancer
-
Human PDGFR a/b Reporter Assay Kit
Species
Human
Target Type
Growth Factor Receptor
Associated Disease
Wound Healing
Growth Factor Receptors
Growth factor receptors are the initial step in a cell’s signaling cascade for cell differentiation and proliferation. The growth signal is initially carried by receptor ligands which then bind to cell-surface receptor tyrosine kinases (RTKs). Growth factor receptors utilize the JAK/STAT, PI3 kinase, and MAP kinase pathways, as well as transcription factors like signal transducers or SMAD proteins. While growth factors act on different cell types, their signal pathways often overlap. This shared mechanism has generated a significant amount of interest in cancer research.
Because of their effect on cell growth, research surrounding growth factor receptors typically focuses on their ability to pinpoint cancer treatments. Once growth factors bind to their receptor, a signal transduction pathway is activated within the cell to ensure the cell is functioning properly. In cancer cells, however, this pathway may never turn on or off. In certain cancers, these receptors are often overexpressed, corresponding to uncontrolled proliferation or differentiation. In addition, the expression of mutant forms of growth factor proteins may also lead to cancer.
Frequently Asked Questions
INDIGO’s assays are not binding assays. They are cell-based trans-activation assays, and the principal application is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that the compounds may exert against the nuclear receptors. INDIGO reporter systems utilize firefly luciferase reporter gene technology, and while there is a binding taking place, our assays do not measure it. Instead, the luciferase light response is measured which correlates to the activation status of the receptor (either activation or inhibition). Quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in receptor activity. It will tell the scientist the significance (strength) of the interaction by the level of light emitted. In addition, cell-based assays are more sensitive and able to detect smaller levels of activation.
INDIGO’s nuclear receptor assays utilize proprietary human and non-human mammalian cells engineered to provide constitutive, high-level expression of the designated receptor. Specific cell type information for each assay is proprietary and available only through consultation with INDIGO’s technical team following a screening service or assay kit purchase.
Reporter cells included in INIDIGO’s steroid hormone nuclear assay kits (ERα, ERβ, AR, PGR, MR, GR) express the native, full-length receptors. INDIGO’s other nuclear receptor assays, however, include reporter cells that express hybrid nuclear receptors. In these cases, the respective receptor’s native N-terminal sequence comprising the DNA Binding Domain (DBD) has been replaced with sequence encoding the yeast Gal4-DBD. All other native NR functional/structural domains (ligand binding domain, hinge region, and various activation domains) are present in these hybrid receptors. These reporter cells also contain the firefly luciferase reporter gene functionally linked to the upstream genetic response element for Gal4. Consequently, once a bioactive compound associates with the ligand binding domain of the hybrid receptor, only the luciferase reporter gene is induced. Ligand-activation of the hybrid receptor will not induce collateral expression of target genes that are otherwise regulated by the native nuclear receptor.
View our list of reference compounds. We do utilize commercially available reference agonists for our assays, and this reference agonist is included in each assay kit. We do use reference antagonists where a reference is known and commercially available. Some of our antagonist assays do not have reference antagonists available.
Each kit includes luciferase reporter cells, an assay plate, all required reagents (optimized culture media, positive-control agonist, and detection reagent), and a detailed Technical Manual. A luminometer is required for Relative Light Unit (RLU) measurements.
INDIGO’s kits are intended for research purposes only, and not for diagnostic or therapeutic use in humans.